Details for New Drug Application (NDA): 012193
✉ Email this page to a colleague
NDA 012193 describes SER-AP-ES, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the SER-AP-ES profile page.
The generic ingredient in SER-AP-ES is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
The generic ingredient in SER-AP-ES is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for 012193
| Tradename: | SER-AP-ES |
| Applicant: | Novartis |
| Ingredient: | hydralazine hydrochloride; hydrochlorothiazide; reserpine |
| Patents: | 0 |
Profile for product number 005
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;15MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
